Is Lenvatinib included in medical insurance?

The original drug Lenvatinib has been marketed in China and has now entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Administration. It is a receptor tyrosine kinase inhibitor used to treat metastatic thyroid cancer, advanced renal cell carcinoma, endometrial cancer and unresectable hepatocellular carcinoma in combination with everolimus. Lenvatinib is sold in the country under the trade name Lenvima.

Lenvatinib Active substance in Lenvatinib is a tyrosine kinase inhibitor, which means that it blocks the activity of tyrosine kinase. These enzymes can be found in certain receptors on cancer cells, such as the VEGF, FGFR and RET receptors, where they activate several processes including cell division and the growth of new blood vessels. By blocking these enzymes, lenvatinib prevents the formation of new blood vessels, cutting off the blood supply that keeps cancer cells growing and reducing their growth. Lenvatinib may also change the activity of the immune system (the body's natural defense system).

Lenvatinib Original drug, specifications4mg*30 capsules available in China may cost more than 3,000 yuan per box. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be RMB 800 (the price may fluctuate due to exchange rates).